Adjuvant immunotherapy with nonviablemycobacterium smegmatis in resected primary lung carcinoma a randomized clinical trial of 219 patients
| العنوان: | Adjuvant immunotherapy with nonviablemycobacterium smegmatis in resected primary lung carcinoma a randomized clinical trial of 219 patients |
|---|---|
| المؤلفون: | Vincent Morice, Jacques Grosset, F. Gremy, Bernard Asselain, Lucien Toty, Georges Hinault, Chantal Fabre, Bernard Lebeau, Claude Chastang, Thierry Lepage, Philippe Daumet, Joseph Sauvaget, Claude Soubrane, Paul Herzog, Jean‐Louis ‐L Rebischung, Michel Jagueux, Jean‐Louis ‐L Accard, Jacques Rochemaure, Pierre Babo, Guy Decroix, Dominique Fichet |
| المصدر: | Cancer. 53:906-912 |
| بيانات النشر: | Wiley, 1984. |
| سنة النشر: | 1984 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, business.industry, medicine.drug_class, Proportional hazards model, medicine.medical_treatment, Immunotherapy, medicine.disease, Interim analysis, Gastroenterology, Immunostimulant, Surgery, law.invention, Subcutaneous injection, Oncology, Randomized controlled trial, law, Internal medicine, Carcinoma, Medicine, business, Adjuvant |
| الوصف: | Two hundred and nineteen patients with resected lung carcinoma were randomized 3 weeks after surgery between two treatment arms: a control group (110 cases) and an immunotherapy group (109 cases). The immunostimulant was a nonviable saprophytic mycobacterium, M. smegmatis, given monthly by subcutaneous injection in four sites. The two groups were equivalent in terms of prognostic factors, including a nonsignificant difference favoring the control group based on the N (node) classification. This interim analysis was carried out on June 1, 1981. Treatment comparison by the log-rank test did not show any significant differences between these two groups in regards to disease-free interval and overall survival. There was no significant difference between the two groups after stratification of the comparison according to the N classification or adjustment with a subset of eight prognostic parameters through the Cox model. The initially expected difference (20% 1-year survival) will probably not be achieved, given these interim results, but patients will continue to be treated and followed-up according to the protocol as to allow further evaluation of this nonspecific immunotherapy. |
| تدمد: | 1097-0142 0008-543X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::c7f0c03d2f737a381c0aea99bd2140b4 https://doi.org/10.1002/1097-0142(19840215)53:4<906::aid-cncr2820530415>3.0.co;2-h |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........c7f0c03d2f737a381c0aea99bd2140b4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10970142 0008543X |
|---|